Glp1 Receptor Agonists
-
{
- All
- News
-
Struggling To Lose Weight On Ozempic, Mounjaro? Study Says Your Genes Might Be the Hurdle
A new study reveals that your genes could be the hidden hurdle, explaining the differences in how bodies respond to weight loss drugs.
-
GLP-1 Should Not Be Used As A Quick Fix For Weight Loss And Diabetes Management, Warns Top Experts
Experts warn that GLP1 drugs like Ozempic and Wegovy aren't quick fixes. There are misuse risks that are involved as shortages, side effects, and weight regain are possible without medical supervision.
-
Indian Pharma Giants Launch Low-Cost Generic Semaglutide Injections For Diabetes, Weight Management
New Delhi, March 21 (IANS) Three Indian pharmaceutical companies have launched generic versions of semaglutide injections, after the drug’s patent expired, offering lower‑cost options for patients managing Type 2 diabetes and obesity.
-
Weight-loss Drugs Linked To Preterm Birth Risk In Women With Pre-Existing Diabetes
The research analysed data from more than 750,000 pregnancies, making it one of the largest studies to examine this issue so far.
-
What Are Semaglutide Generics? Here's Why They Matter More In India Now
Semaglutide works by imitating the natural hormone glucagon-like peptide-1 (GLP-1), which plays a key role in managing blood sugar.
-
Weight-Loss Surgery May Protect Your Heart More Than Drugs Like Ozempic, Mounjaro: Study
A new study suggests bariatric surgery may offer stronger long-term heart protection than GLP-1 drugs like Ozempic and Mounjaro.
-
Ozempic Teeth? Dentist Warns Of New Side Effect Linked To Tooth Decay And Cavities
Ozempic is the brand name for a GLP 1 receptor agonist prescribed for type 2 diabetes.
-
New Study Links Popular Diabetes Drugs To Reduced Risk Of Strokes
GLP-1RA drugs may lower risk of deadly subarachnoid haemorrhage strokes in diabetes patients.
-
Some Diabetes Patients Achieve Remission With GLP-1 Drugs: Italian Study
An Italian study shows that using GLP-1 receptor agonists can lead to remission in up to 18% of cases, especially when used early and in patients with fewer complications.
-
Struggling To Lose Weight On Ozempic, Mounjaro? Study Says Your Genes Might Be the Hurdle
A new study reveals that your genes could be the hidden hurdle, explaining the differences in how bodies respond to weight loss drugs.
-
GLP-1 Should Not Be Used As A Quick Fix For Weight Loss And Diabetes Management, Warns Top Experts
Experts warn that GLP1 drugs like Ozempic and Wegovy aren't quick fixes. There are misuse risks that are involved as shortages, side effects, and weight regain are possible without medical supervision.
-
Indian Pharma Giants Launch Low-Cost Generic Semaglutide Injections For Diabetes, Weight Management
New Delhi, March 21 (IANS) Three Indian pharmaceutical companies have launched generic versions of semaglutide injections, after the drug’s patent expired, offering lower‑cost options for patients managing Type 2 diabetes and obesity.
-
Weight-loss Drugs Linked To Preterm Birth Risk In Women With Pre-Existing Diabetes
The research analysed data from more than 750,000 pregnancies, making it one of the largest studies to examine this issue so far.
-
What Are Semaglutide Generics? Here's Why They Matter More In India Now
Semaglutide works by imitating the natural hormone glucagon-like peptide-1 (GLP-1), which plays a key role in managing blood sugar.
-
Weight-Loss Surgery May Protect Your Heart More Than Drugs Like Ozempic, Mounjaro: Study
A new study suggests bariatric surgery may offer stronger long-term heart protection than GLP-1 drugs like Ozempic and Mounjaro.
-
Ozempic Teeth? Dentist Warns Of New Side Effect Linked To Tooth Decay And Cavities
Ozempic is the brand name for a GLP 1 receptor agonist prescribed for type 2 diabetes.
-
New Study Links Popular Diabetes Drugs To Reduced Risk Of Strokes
GLP-1RA drugs may lower risk of deadly subarachnoid haemorrhage strokes in diabetes patients.
-
Some Diabetes Patients Achieve Remission With GLP-1 Drugs: Italian Study
An Italian study shows that using GLP-1 receptor agonists can lead to remission in up to 18% of cases, especially when used early and in patients with fewer complications.
